← Back to all trials
Recruiting
NCT07458906
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
Conditions: DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 80
Sponsor: The First Affiliated Hospital of Xiamen University
Location: The First Affiliated Hospital of Xiamen University Xiamen Fujian
Summary
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
Eligibility Criteria
Inclusion Criteria:
* Adult patients (aged 18 years or older);
* Patients with suspected, newly diagnosed, and previously treated neuroendocrine carcinoma(supporting evidence may include imaging findings and pathology report);
* Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;
* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;
Exclusion Criteria:
* The inability or unwillingness of the research participant or legal representative to provide written informed consent.
* Inability to complete PET/CT imaging.
Source: ClinicalTrials.gov (NCT07458906). StuddyBuddy aggregates publicly available trial information.
